An innovative Chinese Alzheimer’s drug extracted from brown algae is set to go through clinical trials on 2,000 patients overseas this year. The orally administered drug GV-971 will be tested in 200 clinical centers in North America, the European Union, Eastern Europe, Asia Pacific and other places, according to Green Valley Pharmaceutical Company, one of the drug’s co-developers.
China has already approved the drug. Green Valley Pharmaceutical will complete the global clinical trials in 2024 and submit the New Drug Application to the US Food and Drug Administration and European Medicines Agency in 2025, Xinhua reported.
The results of the mechanism of action study were published in the international journal Cell Research in September 2019, saying that the drug works by modifying gut bacteria to ultimately reduce brain inflammation in mice that were genetically engineered to have the disease.
Well we have been seeing that gut bacteria is pretty key to much of the functioning of the rest of the human body.
#health #alzheimers
#^Chinese Alzheimer’s drug extracted from brown algae to undergo global clinical trials – OrissaPOST
Beijing: An innovative Chinese Alzheimer’s drug extracted from brown algae is set to go through clinical trials on 2,000 patients overseas this year. The orally administered drug GV-971 will be tested in 200 clinical centers in North America, the European Union, Eastern Europe, Asia Pacific and other places, according to Green Valley Pharmaceutical Company, one …